<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02856698</url>
  </required_header>
  <id_info>
    <org_study_id>EUDRACT: 2016-000884-17</org_study_id>
    <nct_id>NCT02856698</nct_id>
  </id_info>
  <brief_title>MIdazolam Versus MOrphine in Acute Pulmonary Edema (MIMO Trial)</brief_title>
  <acronym>MIMO</acronym>
  <official_title>Study Design and Rationale of &quot;A Multicenter, Open-Labeled, Randomized Controlled Trial Comparing MIdazolam Versus MOrphine in Acute Pulmonary Edema&quot;: MIMO Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alberto Dominguez-Rodriguez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario de Canarias</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute pulmonary edema (APE) is a common condition in the emergency room, associated with
      considerable mortality. The use of intravenous morphine in the treatment of APE remains
      controversial and Benzodiazepines have been suggested as an alternative for morphine to
      relieving dyspnoea and anxiety in the patients with APE. The MIdazolan versus MOrphine in APE
      trial (MIMO) is a multicenter, prospective, open-label, randomized study designed to evaluate
      the efficacy and safety of morphine in patients with APE.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 8, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>28 days after of the hospitalization</time_frame>
    <description>In hospital mortality after discharge from the hospital</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation</measure>
    <time_frame>Number of days on ventilator up to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Intensive Care Unit Stay</measure>
    <time_frame>14 days following discharge from care unit stay</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospitalization Stay</measure>
    <time_frame>30 days following discharge from index hospitalization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Acute Pulmonary Edema</condition>
  <arm_group>
    <arm_group_label>midazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose of midazolam intravenously will be of 1 mg which may be repeated until a total dose of 3 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The dose of morphine intravenously is of 2-4 mg which may be repeated until a total dose of 8 mg if the patient continue suffering from severe anxiety or distress caused by APE</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Dose use according to the product technical sheet</description>
    <arm_group_label>midazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Dose use according to the product technical sheet</description>
    <arm_group_label>morphine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with acute pulmonary edema with dyspnoea and anxiety

        Exclusion Criteria:

          -  Patients with known severe liver disease.

          -  Patients with known severe renal disease.

          -  Patients with expectation of death from other illness during the course of the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alberto Domínguez, MD,PhD, FESC</last_name>
    <phone>+34 922678000</phone>
    <email>adrvdg@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía de Córdoba</name>
      <address>
        <city>Córdoba</city>
        <state>Andalucía</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rafael Calvo-Rodríguez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Comarcal de la Axarquía</name>
      <address>
        <city>Málaga</city>
        <state>Andalucía</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Coral Suero-Méndez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oscar Miró, MD</last_name>
      <email>omiro@clinic.ub.es</email>
    </contact>
    <contact_backup>
      <last_name>Victor Gil, MD</last_name>
      <email>vgil@clinic.cat</email>
    </contact_backup>
    <investigator>
      <last_name>Óscar Miró-Andreu</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Víctor Gil-Espinosa</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>Santa Cruz De Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo Burillo-Putze, MD, PhD</last_name>
      <email>gburillo@telefonica.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General de Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pere Llorens, MD, PhD</last_name>
      <email>llorens_ped@gva.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francisco Javier Martín-Sánchez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Reina Sofía</name>
      <address>
        <city>Murcia</city>
        <zip>30003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascual Piñera Salmerón, MD</last_name>
      <email>pascual.pinera@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Comarcal de Axarquia</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Coral Suero, MD</last_name>
      <email>coralsuero@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 20, 2016</study_first_submitted>
  <study_first_submitted_qc>August 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2016</study_first_posted>
  <last_update_submitted>October 30, 2019</last_update_submitted>
  <last_update_submitted_qc>October 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario de Canarias</investigator_affiliation>
    <investigator_full_name>Alberto Dominguez-Rodriguez</investigator_full_name>
    <investigator_title>Alberto Domínguez- Rodríguez, MD, PhD, FESC</investigator_title>
  </responsible_party>
  <keyword>Acute heart failure</keyword>
  <keyword>morphine</keyword>
  <keyword>midazolam</keyword>
  <keyword>in-hospital mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

